Evaluating a Paclitaxel Coated Balloon for Treating Atherosclerosis in Leg Arteries

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the safety and effectiveness of the PAK® DCB Catheter in patients suffering from symptomatic peripheral artery disease (PAD) with stenosis in the superficial femoral and/or popliteal arteries. It focuses on individuals with either new or previously treated atherosclerotic lesions, evaluating their response to this minimally invasive treatment. Participants will undergo endovascular revascularization procedures to improve blood flow and alleviate symptoms of limb ischemia. The study will monitor outcomes related to both performance and safety of the device used.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years.
2. Written informed consent of the patient to participate in the study.
3. Symptoms of lower limb ischemia defined by Rutherford classification from 2 to 4.
4. At least one de novo or restenotic lesion, in SFA and/or PA defined as a lesion with a proximal origin \>10mm from SFA origin and a distal end above the knee joint (at least 3 cm above bottom of the femur- P1).
5. Target Lesion \>60% stenosis in the SFA or PA (based on angio-CT and/or confirmed in angiography).
6. Target Lesion \<150 mm that consists of no more than two adjacent lesions ≤ 25mm apart and is able to be completely covered with inflation of single investigated PAK DCB (with minimum of \>5mm proximal and distal margin.

   Note: Adjacent or tandem lesions must be treated as a single lesion.
7. Reference Vessel Diameter (RVD) between 4.0 and 8.0mm and within treatment range of PAK® DCB to be used 1:1 at the target lesion.
8. Angiographic evidence of distal run-off demonstrated by at least one patent tibial vessel without evidence of significant ≥50% angiographic stenosis from origin to ankle.
9. In-flow vessel (both iliac and femoral) without significant ≥50% angiographic stenosis or successful treatment (≤30% residual stenosis with no complications) of a diseased in-flow vessel at least 30 days prior to the index procedure.

Note: treatment of contralateral iliac arteries is allowed.

Exclusion Criteria:

1. Life expectancy less than 2 years.
2. Suspected or detected malignancy without completed treatment (not considered cured).
3. Planned surgical or interventional procedures within 30 days after the study procedure.
4. Known impaired renal function with GFR ≤30 mL/min per 1.73 m2 and/or elevated serum creatinine \> 2.5mg/dL or on dialysis.
5. Active inflammatory process at the site of the planned puncture.
6. Acute lower limb ischemia.
7. Non-atherosclerotic lesion (e.g. vasculitis, dysplasia).
8. Necessary concurrent non-target lesion interventions involving a re-entry device, atherectomy, laser, or ablation procedures, the use of a drug eluting stent, or treatment with any other drug coated balloon.
9. Massive calcifications of the treated lesion (defined as angiographic evidence of dense calcification present on both sides of the vessel wall on two orthogonal views and that extends \>50 continuous mm in length; reflective 3 or 4 on the PACSS scale https://doi.org/10.1002%2Fccd.25387).
10. Angiographically confirmed presence of a thrombus in the target lesion.
11. The target lesion requiring primary stenting.
12. Presence of perforation, dissection (Type D or worse) or other injury in target vessel at time of enrollment.
13. Previous bypass graft or stent at target vessel (must be greater than 20mm from target lesion), or iliac stent that cannot permit crossing by the treatment balloon within the introducer sheath Note: In-stent restenosis is not allowed.
14. Gastrointestinal or any other major bleeding in the past three months.
15. Known bleeding disorder or uncontrolled hypercoagulable disorder.
16. Myocardial infarction or any stroke within 30 days prior to the procedure.
17. Known intolerance to required medications (especially antiplatelets and heparin), contrast media (that cannot be adequately pre-medicated), nitinol or paclitaxel.
18. Pregnant and childbearing age women not using effective contraception.
19. Participation in another investigational study (before completing primary endpoint analysis) or previous enrollment to this study.

Where it's running

• Department of Vascular Surgery; Malopolska Cardiovascular Center; Polish-American Heart Clinics
  Chrzanów, Malopolska, Poland Recruiting
• University Hospital Clinical Hospital No. 2 PUM in Szczecin, Department of General, Dental and Interventional Radiology
  Szczecin, West Pomeranian Voivodeship, Poland Recruiting
• Vascular Surgery Teaching Unit CardioVascular Institute Hospital Clinic University of Barcelona
  Barcelona, Barcelona, Spain Not yet recruiting

Study contacts

• Study coordinator: Elżbieta Sojka
• Email: elzbieta.sojka@balton.pl
• Phone: (+48) 22 597 44 43

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Antiplatelet-Only versus Antiplatelet plus Low-Dose Rivaroxaban after Heart Events

  In adults 65 or older with prior heart events and certain arterial diseases, this study tests whether continuing clopidogrel alone is no worse than adding low-dose rivaroxaban to aspirin-based therapy.

  Recruiting Phase 4 Seoul National University Bundang Hospital · Seongnam-si, Gyeonggi-do · NCT07796217

• Home-based Pedal Exerise Therapy for Moderate-to-Severe PAD

  This pilot study tests whether a 12-week home-based pedal exerciser program, guided remotely, can help adults with moderate-to-severe PAD improve walking and function.

  Recruiting Laval University · Lévis, Quebec · NCT07655206

• Super-resolution ultrasound imaging for peripheral artery disease

  This project will test whether super-resolution contrast ultrasound can reveal small-vessel problems in adults with or without peripheral artery disease.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07374601

• Obstructive sleep apnea prevalence in people with peripheral artery disease

  This project will test how common obstructive sleep apnea is in adults with peripheral artery disease by using sleep polygraphy during routine care.

  Recruiting Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Toulon, Var · NCT07283289

• Using wearable activity trackers and a mobile app to help people with peripheral artery disease walk better

  This project will test whether a personalized home walking program guided by wearable activity trackers and automatic feedback can help people with peripheral artery disease walk as well as supervised exercise sessions.

  Recruiting at 2 sites Chinese University of Hong Kong · Hong Kong, Hong Kong and 1 other locations · NCT07012070

• Helping people walk better after leg revascularization for peripheral artery disease

  This project will see if adding a home-based walking program or taking nitrate-rich beetroot juice after leg revascularization helps people with peripheral artery disease walk farther and faster.

  Recruiting at 8 sites Phase 3 Northwestern University · Tucson, Arizona and 7 other locations · NCT06686121

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.